Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kazia Therapeutics Ltd KZIA

Healthcare Biotechnology
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor... see more

Recent & Breaking News (NDAQ:KZIA)

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

PR Newswire December 11, 2024

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

PR Newswire November 4, 2024

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

PR Newswire October 2, 2024

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

PR Newswire September 23, 2024

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

PR Newswire September 12, 2024

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

PR Newswire July 10, 2024

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

PR Newswire June 27, 2024

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

PR Newswire May 23, 2024

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

PR Newswire May 1, 2024

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

PR Newswire March 21, 2024

Kazia announces presentation of new data at AACR Annual Meeting

PR Newswire March 13, 2024

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

PR Newswire February 21, 2024

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

PR Newswire January 18, 2024

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

PR Newswire December 5, 2023

Kazia Therapeutics Announces $2 Million Registered Direct Offering

PR Newswire December 1, 2023

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

PR Newswire November 29, 2023

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

PR Newswire November 21, 2023

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

PR Newswire November 20, 2023

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

PR Newswire November 15, 2023

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

PR Newswire November 10, 2023